Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,318 across all filing types
Latest filing 2024-11-14 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015
Regulatory Filings Classification · 100% confidence The document is a formal communication addressed to stock exchanges regarding an order received from a regulatory authority (COFEPRIS, Mexico's health department). It details a penalty imposed on the company for regulatory non-compliance. The document references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an announcement of a regulatory action and penalty, not a financial report, audit, or management discussion. It is a regulatory announcement informing the market about a compliance issue and penalty. The document length is short (2245 characters), and it is not a report or financial statement but an intimation under regulatory disclosure requirements. Therefore, the appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-11-14 English
Loss of Share Certificate(s)
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about the loss of share certificates by shareholders, referencing Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. It lists specific shareholders, folio numbers, certificate numbers, and distinctive numbers. The content is an official announcement related to share certificates but does not contain financial data, management discussion, or report content. It is not a report or financial statement but a regulatory disclosure about share certificate loss. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-11-13 English
6-K Filing
Regulatory Filings
2024-11-12 English
Transcript of earnings call conducted on November 5, 2024
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Dr. Reddy's Laboratories Limited for the quarter and half-year ended September 30, 2024. It includes management commentary, financial highlights, operational updates, and Q&A format typical of earnings call transcripts. The text explicitly mentions it is a transcript of the earnings call conducted on November 5, 2024, and references the release of quarterly results. There is no indication that this is a brief announcement or a report publication notice; rather, it is the full transcript of the call. Therefore, the document fits the definition of a Call Transcript (CT).
2024-11-11 English
Intimation on filing of Form 6-K for the quarter ended September 30, 2024
Regulatory Filings Classification · 95% confidence The document is a short letter informing the stock exchanges about the filing of a Form 6-K with the SEC for the quarter ended September 30, 2024. It states that the Form 6-K, which contains unaudited condensed consolidated interim financial statements, has been filed and is available on the SEC website. The document itself does not contain the financial statements or substantive financial data but merely announces the filing and provides a link. According to the 'Menu vs Meal' rule, such a brief announcement about the filing of a report is classified as a Regulatory Filing (RNS) rather than the report itself (which would be an Interim/Quarterly Report).
2024-11-07 English
6-K Filing
Regulatory Filings
2024-11-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.